Bicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC reduced its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) by 16.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 445,396 shares of the company’s stock after selling 89,667 shares during the period. Bicycle Therapeutics makes up 1.3% of Parkman Healthcare Partners LLC’s holdings, making the stock its 26th largest position. Parkman Healthcare Partners LLC owned approximately 0.94% of Bicycle Therapeutics worth $10,079,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of BCYC. Assetmark Inc. acquired a new position in Bicycle Therapeutics in the third quarter valued at approximately $34,000. GAMMA Investing LLC boosted its holdings in Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after buying an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares during the last quarter. XTX Topco Ltd acquired a new stake in Bicycle Therapeutics in the 2nd quarter valued at about $206,000. Finally, Crossmark Global Holdings Inc. acquired a new position in shares of Bicycle Therapeutics during the 3rd quarter valued at about $257,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Wall Street Analyst Weigh In

BCYC has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Oppenheimer reaffirmed an “outperform” rating and issued a $48.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, September 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Finally, B. Riley downgraded shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the company from $33.00 to $28.00 in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.13.

Insider Buying and Selling

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the transaction, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin Lee sold 3,212 shares of the stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at $8,478,032.64. This trade represents a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,840 shares of company stock worth $259,128 in the last ninety days. Insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Trading Down 2.8 %

BCYC stock opened at $19.45 on Wednesday. The company’s 50-day moving average price is $23.34 and its 200 day moving average price is $22.92. Bicycle Therapeutics plc has a 52 week low of $14.33 and a 52 week high of $28.67. The company has a market cap of $924.85 million, a P/E ratio of -5.91 and a beta of 0.86.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. The firm had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics’s revenue was down 50.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.26) earnings per share. On average, equities research analysts expect that Bicycle Therapeutics plc will post -3.07 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.